Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Imatinib resistance: Obstacles and opportunities
Mark R. Litzow
Hematology
Research output
:
Contribution to journal
›
Article
›
peer-review
48
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Imatinib resistance: Obstacles and opportunities'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Imatinib Mesylate
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
30%
Chromosomes, Human, Pair 22
19%
Chromosomes, Human, Pair 9
19%
Philadelphia Chromosome
18%
Hematologic Neoplasms
14%
Cytogenetics
14%
Protein-Tyrosine Kinases
13%
Information Storage and Retrieval
13%
MEDLINE
12%
Leukemia
11%
Phosphotransferases
11%
Proteins
10%
Clinical Trials
9%
Mutation
8%
Therapeutics
7%
Pharmaceutical Preparations
6%